Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant

Journal of Molecular Biology

Volumn 264, Issue 5, 1996, Pages 1085-1100

  Kalyan, Das ^a   Ding, Jianping ^a   Hsiou, Yu ^a   Clark Jr , Arthur D ^a   Moereels, Henri ^b   Koymans, Luc ^b   Andries, Koen ^b   Pauwels, Rudi ^c   Janssen, Paul A J ^b   Boyer, Paul L ^d   Clark, Patrick ^d   Smith Jr , Richard H ^d,e   Kroeger Smith, Marilyn B ^d   Michejda, Christopher J ^d   Hughes, Stephen H ^d   Arnold, Edward ^a  

^a RUTGERS UNIVERSITY   (United States)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c TIBOTEC BVBA   (Belgium)

^d NATIONAL CANCER INSTITUTE   (United States)

^e WESTERN MARYLAND COLLEGE   (United States)

Author keywords

Antiviral inhibitors; Drug design; Drug resistance; Protein structure; Reverse transcriptase

Indexed keywords

9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; ANTIVIRUS AGENT; MUTANT PROTEIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIVIRAPINE; VIRUS ENZYME;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; ENZYME INHIBITOR COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT;

EID: 0030596068     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1996.0698     Document Type: Article

References (61)

1. Arnold, E., Jacobo-Molina, A., Nanni, R. G., Williams, R. L., Lu, X., Ding, J., Clark, A. D., Jr, Zhang, A., Ferris, A. L., Clark, P., Hizi, A. & Hughes, S. H. (1992). Structure of HIV-1 reverse transcriptase/DNA complex at 7 Å resolution showing active site locations. Nature, 357, 85-89.
2. Arnold, E., Das, K., Ding, J., Yadav, P. N. S., Hsiou, Y., Boyer, P. L. & Hughes, S. H. (1996). Targeting HIV reverse transcriptase for anti-AIDS drug design. Drug Design Discov. 13, 29-47.
3. Balzarini, J., Karlsson, A., Perez-Perez, M.-J., Vrang, L., Walbers, J., Zhang, H., Oberg, B., Vandamme, A.-M., Camarasa, M.-J. & De Clercq, E. (1993a). HIV-1-specific reverse transcriptase inhibitors show differential activity against mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology, 192, 246-253.
4. Balzarini, J., Karlsson, A., Perez-Perez, M. J., Camarasa, M. J., Tarpley, W. G. & De Clercq, E. (1993b). Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67, 5353-5359.
5. Boessenkool, I. K. & Boeyens, J. A. (1980). Identification of the configurational type of seven-membered rings. J. Cryst. Mol. Struct. 10, 11-18.
6. Boyer, P. L., Ding, J., Arnold, E. & Hughes, S. H. (1994). Drug resistance of human immunodeficiency virus type 1 reverse transcriptase: subunit specificity of mutations that confer resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 38,1909-1914.
7. Brünger, A. T. (1992). The free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature, 355, 472-474.
8. Brünger, A. T. (1993). X-PLOR Manual version 3.1: a system for X-ray crystallography and NMR. Yale University Press, New Haven and London.
9. Byrnes, V. W., Sardana, V. V., Schleif, W. A., Condra, J. H., Waterbury, J. A., Wolfgang, J. A., Long, W. J., Schneider, C. L., Schlabach, A. J., Wolanski, B. S., Graham, D. A., Gotlib, L., Rhodes, A., Titus, D. L., Roth, E., Blahy, O. M., Quintero, J. C., Staszewski, S. & Emini, E. A. (1993). Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 37, 1576-1579.
10. Carson, M. (1987). Ribbon models of macromolecules. J. Mol. Graph. 5, 103-106.
11. Clark, A. D., Jr, Jacobo-Molina, A., Clark, P., Hughes, S. H. & Arnold, E. (1995). Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors, and an antibody Fab fragment. Methods Enzymol. 262, 171-185.
12. Collaborative Computational Project No. 4 (1994). The CCP4 suite: programs for protein crystallography. Acta Crystallog. sect. D, 50, 760-763.
13. Cowtan, K. (1994). Dmmulti. Joint CCP4 and ESF-EACBM Newsletter on Protein Crystallography, 31, 34-38.
14. De Clercq, E. (1994). HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47, 155-169.
15. De Clercq, E. (1995a). Antiviral therapy of human immunodeficiency virus infections. Clin. Microbiol. Rev. 8, 200-239.
16. De Clercq, E. (1995b). Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 38, 2491-2517.
17. Ding, J., Das, K., Moereels, H., Koymans, L., Andries, K., Janssen, P. A. J., Hughes, S. H. & Arnold, E. (1995a). Structure of HIV-1 RT/TIBO R 86183 reveals similarity in the binding of diverse non-nucleoside inhibitors. Nature Struct. Biol 2, 407-415.
18. Ding, J., Das, K., Tantillo, C., Zhang, W., Clark, A. D., Jr, Jessen, S., Lu, X., Hsiou, Y., Jacobo-Molina, A., Andries, K., Pauwels, R., Moereels, H., Koymans, L., Janssen, P. A. J., Smith, R., Koepke, M. K., Michejda, C., Hughes, S. H. & Arnold, E. (1995b). Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure, 3, 365-379.
19. Dueweke, T. J., Pushkarskaya, T., Poppe, S. M., Swaney, S. M., Zhao, J. Q., Chen, I. S. Y., Stevenson, M. & Tarpley, W. G. (1993). A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other non-nucleoside inhibitors. Proc. Natl Acad. Sci. USA, 90, 4713-4717.
20. Esnouf, R., Ren, J., Ross, R., Jones, Y., Stammers, D. & Stuart, D. (1995). Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct. Biol. 2, 303-308.
21. Evans, P. R. (1993). Data reduction. In Data Collection and Processing (Sawyer, L., Issacs, N. & Bailey, N., eds), pp. 114-122, SERC Daresbury Laboratory, Daresbury, UK.
22. Hendrickson, W. A. (1985). Stereochemically restrained refinement of macromolecular structures. Methods Enzymol 115, 252-270.
23. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M. & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 373, 123-126.
24. Hopkins, A. L., Ren, J., Esnouf, R. M., Willcox, B. E., Jones, E. Y., Ross, C., Miyasaka, T., Walker, R. T., Tanaka, H., Stammers, D. K. & Stuart, D. I. (1996). Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39, 1589-1600.
25. Hsiou, Y., Ding, J., Das, K., Clark, A. D., Jr, Hughes, S. H. & Arnold, E. (1996). Structure of unliganded human immunodeficiency virus type 1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure, 4, 853-860.
26. Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Jr, Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., Hizi, A., Hughes, S. H. & Arnold, E. (1993). Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl Acad. Sci. USA, 90, 6320-6324.
27. Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. A, 47, 110-119.
28. Kleywegt, G. J. & Jones, T. A. (1994a). Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallog. sect. D. 50, 178-185.
29. Kleywegt, G. J. & Jones, T. A. (1994b). Halloween, masks and bones. In From First Map to Final Model (Bailey, S., Hubbard, R. & Waller, D., eds), pp. 59-66, SERC Daresbury Laboratory, Daresbury, U.K.
30. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. & Steitz, T. A. (1992). Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256, 1783-1790.
31. Larder, B. A. (1992). 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to non-nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36, 2664-2669.
32. Larder, B. A. (1993). Inhibitors of HIV reverse transcriptase as antiviral agents and drug resistance. (1993) In Skalka, A. M., Goff, S. P., eds, Reverse Transcriptase. pp. 205-222. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
33. Liaw, Y. C., Gao, Y. G., Robinson, H. & Wang, A. H. J. (1991). Molecular structure of a potent HIV-1 inhibitor belonging to TIBO family. J. Am. Chem. Soc. 113, 1857-1859.
34. Minor, W. (1993). XDISPLAYF program. Purdue University, West Lafayette, IN, USA.
35. Nanni, R. G., Ding, J., Jacobo-Molina, A., Hughes, S. H. & Arnold, E. (1993). Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design. Perspect. Drug Discov. Design, 1, 129-150.
36. Nunberg, J. H., Schleif, W. A., Boots, E. J., O'Brien, J. A., Quintero, J. C., Hoffman, J. M., Emini, E. A. & Goldman, M. E. (1991). Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65, 4887-4892.
37. Otwinowski, Z. (1993). Oscillation data reduction program. In Data Collection and Processing (Sawyer, L., Issacs, N. & Bailey, S., eds), pp. 55-62, SERC Daresbury Laboratory, Daresbury, U.K.
38. Pauwels, R., Andries, K., Debyser, Z., Van Daele, P., Schols, D., Stoffels, P., De Vreese, K., Woestenborghs, R., Vandamme, A.-M., Janssen, C. G. M., Anne, J., Cauwenbergh, G., Desmyter, J., Heykants, J., Janssen, M. A. C., De Clercq, E. & Janssen, P. A. J. (1993). Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl Acad. Sci. USA, 90, 1711-1715.
39. Pauwels, R., Andries, K., Debyser, Z., Kukla, M. J., Schols, D., Breslin, H. J., Woestenborghs, R., Desmyter, J., Janssen, M. A. C., De Clercq, E. & Janssen, P. A. J. (1994). New TIBO derivatives are potent inhibitors of HIV-1 replication and are synergistic with 2′,3′-dideoxynucleoside analogues. Antimicrob. Agents Chemother. 38, 2863-2870.
40. Read, R. J. (1986). Improved Fourier coefficients or maps using phases from partial structures with errors. Acta Crystallog. sect. A, 42, 140-149.
41. Ren, J., Esnouf, R., Carman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Darby, G., Jones, Y., Stuart, D. & Stammers, D. (1995a). High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol. 2, 293-302.
42. Ren, J., Esnouf, R., Hopkins, A., Ross, C., Jones, Y., Stammers, D. & Stuart, D. (1995b). The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure, 3, 915-926.
43. Richman, D. D. (1993). Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37, 1207-1213.
44. Richman, D., Shih, C. K., Lowy, I., Rose, J., Prodanovich, P., Goff, S. & Griffin, J. (1991). Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl Acad. Sci. USA, 88, 11241-11245.
45. Richman, D. D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S. A., Sullivan, J., Cheeseman, S., Barringer, K., Pauletti, D., Shih, C-K., Myers, M. & Griffin, J. (1994). Nevirapine resistance mutations of HIV-1 selected during therapy. J. Virol. 68, 1660-1666.
46. Rittinger, K., Divita, G. & Goody, R. (1995). Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by non-nucleoside inhibitors. Proc. Natl Acad. Sci. USA, 92, 8046-8049.
47. Rodgers, D. W. (1994). Cryocrystallography. Structure, 2, 1135-1140.
48. Rodgers, D. W., Gamblin, S. J., Harris, B. A., Ray, S., Culp, J. S., Hellmig, B., Woolf, D. J., Debouck, C. & Harrison, S. C. (1995). The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA, 92, 1222-1226.
49. Sarafianos, S. G., Das, K., Ding, J., Hsiou, Y., Hughes, S. H. & Arnold, E. (1996). Current perspectives on mechanisms of HIV-1 reverse transcriptase inhibition by nonnucleoside inhibitors. In Anti-Infectives: Recent Advances in Chemistry and Structure Activity Relationships (Bentley, P. H. &O'Hanlon, P. J., eds), The Royal Society of Chemistry, Cambridge, England. In the Press.
50. Sardana, V. V., Emini, E. A., Gotlib, L., Graham, D. J., Lineberger, D. W., Long, W. J., Schlabach, A. J., Wolfgang, J. A. & Condra, J. H. (1992). Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple non-nucleoside inhibitors. J. Biol. Chem. 267, 17526-17530.
51. Schinazi, R. F. (1993). Competitive inhibitors of human immunodeficiency virus reverse transcriptase. Perspec. Drug Discov. Design, 1, 151-180.
52. Smerdon, S. J., Jager, J., Wang, J., Kohlstaedt, L. A., Chirino, A. J., Friedman, J. M., Rice, P. A. & Steitz, T. A. (1994). Structure of the binding site for non-nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA, 91, 3911-3915.
53. Smith, M. B. K., Rouzer, C. A., Taneyhill, L. A., Smith, N. A., Hughes, S. H., Boyer, P. L., Janssen, P. A. J., Moereels, H., Koymans, L., Arnold, E., Ding, J., Das, K., Zhang, W., Michejda, C. J. & Smith, R. H., Jr (1995). Molecular modeling studies of HIV-1 reverse transcriptase non-nucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Protein Sci. 4, 2203-2222.
54. Spence, R. A., Kati, W. M., Anderson, K. S. & Johnson, K. A. (1995). Mechanism of inhibition of reverse transcriptase by non-nucleoside inhibitors. Science, 267, 988-993.
55. Spence, R. A., Anderson, K. S. & Johnson, K. A. (1996). HIV-1 reverse transcriptase resistance to non-nucleoside inhibitors. Biochemistry, 35, 1054-1063.
56. Stura, E. A. & Wilson, I. A. (1990). Analytical and production seeding techniques. Methods, 1, 38-49.
57. Tantillo, C., Ding, J., Jacobo-Molina, A., Nanni, R. G., Boyer, P. L., Hughes, S. H., Pauwels, R., Andries, K., Janssen, P. A. J. & Arnold, E. (1994). Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243, 369-387.
58. Teng, T. Y. (1990). Mounting of crystals for macromolecular crystallography in a free-standing thin film. J. Appl. Crystallog. 24, 387-391.
59. Vandamme, A.-M., Debyser, Z., Pauwels, R., DeVreese, K., Goubau, P., Youle, M., Gazzard, B., Stoffels, P. A., Cauwenbergh, C. F., Anne, J., Andries, K., Janssen, P. A. J., Desmyter, J. & De Clerq, E. (1994). Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. AIDS Res. Human Retro. 10, 39-46.
60. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S. & Shaw, G. M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature, 373, 117-122.
61. Young, S. D. (1993). Non-nucleoside inhibitors of HIV-1 reverse transcriptase. Perspect. Drug Discov. Design, 1, 181-192.